Next Science (ASX:NXS) said that former employee Michael Morello has filed a derivative complaint in Florida's Duval County Court, alleging breaches of fiduciary duties and mismanagement by several employees, according to a Wednesday filing with the Australian bourse.
Morello, who was Vice President of Wound Care Sales until December 2023, is also involved in a separate legal case initiated by the company in May 2024, alleging that he and other former employees breached post-employment restraints, the filing said.
Meanwhile, Morello's complaint claims Next Science's XBIO technology is not FDA-approved for biofilm eradication, and safety concerns about its Xperience surgical solution in breast implant procedures were not addressed, the filing added.
The company asserts that its products are FDA-approved, safe, and effective.
Next Science is conducting an independent investigation and will continue pursuing its non-compete action against Morello and former employees.
Shares of the company rose past 4% on market close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.